RESEARCH REPORT
Merck & Company, Inc.
MRK
$146.73
As of 2026-11-08
Research note — 2026-11-08. Educational analysis, not financial advice.
The one-line version
Merck & Company, Inc. trades near $146.73 on a trailing multiple of about 148.2x versus its own 5-year median near 104.2x, against contested Street targets and the usual concentration and execution risks. That's the tension. Everything below is the detail.
That's the tension. Everything below is the detail.
1. What you're paying
| Now | Its own 5-year median | Gap | |
|---|---|---|---|
| P/E (trailing) | ~148.2 | ~104.2 | +42% |
| P/E (forward) | ~16.3 | — | — |
| EPS (TTM) | 0.99 | — | — |
| Gross margin | 75.2% | — | — |
What that means in plain terms: the gap versus the company's own history is the growth or durability the market is already pricing. It is not automatically wrong — it is the bet.
Fair-value anchors on file:
- 5-year median P/E multiple: $103.13 — Applies the 5-year median multiple (104.2x) to trailing EPS.
- Street mean target: $161.53 — Average published analyst target.
- Street target midpoint: $145.50 — Midpoint of $105.00–$186.00 published range.
Street targets run from $105.00 to $186.00. A wide spread means the name is contested, not consensus.
2. What the bulls are counting on
- Street coverage and recent filings supply the constructive case; pull the latest 10-Q for segment detail.
Sign up free to read the full analysis
Bull case, bear case, assumptions, and what to watch next.
3. What the bears see
- Multiple risk: paying above the company's own history embeds growth that still has to show up in the numbers.
- Concentration and execution: watch customer, geography, and product-cycle dependency in the next filings.
Sign up free to read the full analysis
Bull case, bear case, assumptions, and what to watch next.
4. What would have to be true
For the stock to justify ~148.2x rather than its 5-year ~104.2x, roughly all of the following need to neutral:
- Growth or margin durability shows up in the next several reports, not just in narrative.
- Key revenue concentrations survive competitive and regulatory pressure.
- Execution on the current product or services cycle stays on schedule.
- The Street target range compresses as results clarify the contested assumptions.
Ask yourself honestly: how many of those would you bet on individually? Multiply your answers together.
Sign up free to read the full analysis
Bull case, bear case, assumptions, and what to watch next.
5. What to watch next
- Next earnings date: 1793277000
- Trailing and forward multiples versus the company's own history
- Segment growth rates in the next 10-Q / earnings release
- Material Form 4 and 13F changes
- Whether the Street high-to-low target spread narrows or widens
Sign up free to read the full analysis
Bull case, bear case, assumptions, and what to watch next.
6. What this note does not do
It doesn't tell you to buy or sell. It won't, ever.
You have the valuation in context, the strongest version of both cases, and the specific assumptions the current price depends on. What you do with that depends on your time horizon, your existing exposure, your risk tolerance, and what else you could do with the money — none of which we know.
If you want someone to tell you what to do, you want a licensed financial adviser, and that is a genuinely reasonable thing to want.
Educational and informational purposes only. Not investment advice and not a recommendation to buy or sell any security. GetStockReport is not a registered investment adviser. Figures are as of 2026-11-08 and go stale quickly — verify against primary sources before acting. All investments carry risk including loss of principal. Past performance does not guarantee future results.
8. Analyst ratings & targets
No recent activity
Analyst opinions change frequently. Past upgrades do not predict future returns.
9. Important news
Nov 11, 2026|Want a Dividend Check Every Month? This Dividend ETF Paid You 12 Times in the Past Year(Yahoo)
A deposit lands every month, but the amounts swing by nearly four times from the smallest check to the largest. Before you build a retirement budget around this fund, see what drives the swings and who should skip it.
Nov 11, 2026|Can You Make Money Off Halozyme Stock Now?(Yahoo)
For questions about this article or underlying research, email help@trefis.com.
Nov 11, 2026|Americans Fill Prescriptions Every Month, and $90,000 Across These 3 Drugmakers Pays $3,650 a Year(Yahoo)
Pharmacy counters stay busy in every kind of market. Blood thinners, cancer drugs, and vaccines get refilled on schedule, and the companies that make them return part of those sales to shareholders as dividends. For retirees, that steady demand can become a steady paycheck. There’s a catch, and it’s called a patent cliff. A patent […]
Nov 11, 2026|Why This Legendary Investor Says to Look Beyond Tech—and the U. S.—for Values(Yahoo)
Rob Arnott has sold the Research Affiliates index business and his firm has a new name. But he’s following the same approach to active value investing.
Target biopharma, gene editing and sustainable agriculture; leverage regional and competitive insights to uncover revenue opportunities and guide R&D investmentDublin, Nov. 11, 2026 (GLOBE NEWSWIRE) -- "Biotechnology - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering. The global biotechnology market was valued at US$2.1 trillion in 2025 and is projected to reach US$5.0 trillion by 2032, expanding at a compound annual growth rate (CAGR) of 13.3%. Market growth
News headlines are reported as-is. Verify important claims with original sources.
10. Insider Form 4 activity
| Date | Executive | Action | Shares | Value |
|---|---|---|---|---|
| Nov 1, 2026 | DIAZ PAUL J | Sell | 613.073 | $91,666.67 |
Form 4 filings are routine transactions. Scheduled sales (10b5-1 plans) are normal and not signals.
11. Institutional 13F holdings
| Fund | Shares | Position | Change |
|---|---|---|---|
| Vanguard Group | 229,006,389 | $24.1B | — |
| State Street | 120,413,256 | $15.6B | — |
| BlackRock | 75,200 | $9.3B | — |
| BlackRock Institutional Trust | 12,473,411 | $734.3M | — |
These are 45-day lagged filings (SEC requirement). Position changes happened in the past.
12. Earnings this week
No recent activity
Earnings dates are estimates and may shift. EPS estimates are consensus, not predictions.